In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii

Journal of Infectious Diseases

Volumn 181, Issue 5, 2000, Pages 1629-1634

  Atzori, Chiara ^a   Angeli, Elena ^a   Mainini, Annalisa ^a   Agostoni, Fiorenza ^a   Micheli, Valeria ^a   Cargnel, Antonietta ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; PEPSTATINS; PNEUMOCYSTIS; PNEUMOCYSTIS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; SAQUINAVIR;

EID: 0034129971     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315437     Document Type: Article

References (42)

1. 1. Simonds RJ, Hughes WT, Feinberg J, Navin TR. Preventing Pneumocrstis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:544-8.
2. 2. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.
3. 3. Schneider M, Borleff JCC, Stolck R, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3.
4. + T cells homeostasis and function in advanced HIV disease. Science 1997;227:112-6.
5. 5. Palella FJ, Delaney KM, Moornian AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
6. 6. Carruthers VB, Sibley LD. Two parasite-derived proteases cleave MIC2 on the surface of T. gondii [abstract W104]. In: Program and abstracts of the 52nd annual meetings of the Society of Protozoologists and the 6th International Workshops on Opportunistic Protists (Raleigh, NC). Raleigh, NC: The Society of Protozoologists, 1999:3.
7. 7. De Bernardis F, Chiani P, Ciccozzi M, et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996;64:466-71.
8. 8. Cauda R, Tacconelli E, Tumbarello E, et al. The role of protease inhibitors in preventing recurrent oral candidiasis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999;21: 20-5.
9. 9. Flexner C. HIV prolease inhibitors. N Engl J Med 1998;338:1281-92.
10. 10. Atzori C, Means IK, Bartlett MS, Smith JW, Queener S. Detection of P. carinii protease using gelatin SDS-PAGE. Dallas, TX: American Society for Microbiology, 1991:B98.
11. 11. Wada M, Nakamura Y. cDNA cloning and overexpression of cell surface subtilisin-like proteases (SSP) of Pneumocystis carinii. J Eukaryot Microbiol 1997;44:54S.
12. 12. Wada M, Nakamura Y. Immunological characterization of surface subtilisin-like protease (SSP) of Pneumocystis carinii [abstract W90]. In: Program and abstracts of the 52nd annual meetings of the Society of Protozoologists and the 6th International Workshops on Opportunistic Protists (Raleigh, NC). Raleigh, NC: The Society of Protozoologists, 1999:59.
13. 13. Lugli EB, Allen A, Wakefield AE. A Pneumocystis carinii multi-gene family with homology to subtilisin-like serine proteases. Microbiology 1997;143: 2223-36.
14. 14. Lugli EB, Bampton ET, Ferguson DJ, Wakefield AE. Cell surface protease PRT1 identified in the fungal pathogen Pneumocystis carinii. Mol Microbiol 1999;31:1723-33.
15. 15. Lugli EB, Bampton ET, Ferguson DJ, Wakefield AE. Surface localization of PRT1, the subtilisin-like serine protease from Pneumocystis carinii f. sp. carinii [abstract W91]. In: Program and abstracts of the 52nd annual meetings of the Society of Protozoologists and the 6th International Workshops on Opportunistic Protists (Raleigh, NC). Raleigh, NC: The Society of Protozoologists, 1999:59.
16. 16. Atzori C, Mainini A, Agostoni F, et al. Detection of rat Pneumocystis carinii proteinases and elastase and antipneumocystis activity of proteinase inhibitors in vitro. Parasite 1999;6:9-16.
17. 17. Queener SF, Burtlett MS, Nasr M, Smith JW. 8-Aminoquinolines effective against Pneumocystis carinii in vivo and in vitro. Antimicrob Agents Chemother 1993;37:2166-72.
18. 18. Queener SF, Bartlett MS, Richardson JD, Durkin MM, Jay MA, Smith JW. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1988;32:807-13.
19. 19. Bartlett MS, Queener SF, Tidwell RR, et al. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother 1991; 35:277-82.
20. 20. Semenov A, Olson J, Rosenthal P. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother 1998;42: 2254-8.
21. 21. Bartlett MS, Fishman JA, Queener SF, Durkin MM, Jay MA, Smith JW. New rat model of Pneumocystis carinii infection. J Clin Microbiol 1988; 26:1100-3.
22. 22. Lee CH, Bauer NL, Shaw MM, et al. Proliferation of rat Pneumocystis carinii on cells sheeted on micro carrier beads in spinner flasks. J Clin Microbiol 1993;31:1659-62.
23. 23. Lockwood BC, North MJ, Scott KI, Bremner AF, Coombs GH. The use of a highly sensitive electrophoretic method to compare the protease of Trichomonas. Mol Biochem Parasitol 1987;24:89-95.
24. 24. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: update recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
25. + T-cell repertoire that are not immediately restored by antiretroviral or immune-based therapies. Nat Med 1997;3:533-40.
26. 26. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:318-26.
27. 27. Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regime [abstract LB-22]. In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:18.
28. 28. Lederberger B, Egger M, Opravil M, et al. Highly active antiretroviral therapy: low rate of clinical disease progression despite high rates of virological failure. Lancet 1999;353:863-8.
29. 29. Rao JK, Erickson JW, Wlodawer A. Structural and evolutionary relationships between retroviral and eukaryotic aspartic proteinases. Biochemistry 1990;30:4663-71.
30. 30. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV protease inhibitors. Science 1990;248:358-61.
31. 31. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;352:1881-3.
32. 32. Harris JO, Olsen GN, Castle JR, Maloney AS. Comparison of proteolytic enzyme activity in pulmonary alveolar macrophages and blood leukocytes in smokers and nonsmokers. Am Rev Respir Dis 1975;111:579-86.
33. 33. Stockley RA. Chronic bronchitis: the antiproteinase-proteinase balance and the effect of infection and corticosteroids. Clin Chest Med 1988;9:643-56.
34. 34. Wada M, Sunkin SM, Stringer JR, Nakamura Y. Antigenic variation by positional control of major surface glycoprotein gene expression in Pneumocystis carinii. J Infect Dis 1995;171:1563-8.
35. 35. Pottratz ST, Martin WM. Mechanisms of Pneumocystis attachment to cultured rat alveolar macrophages. J Clin Invest 1990;86:1678-93.
36. 36. Smulian AG, Theus SA, Denko N, Walzer PD, Stringer JR. A 55 kDa antigen of Pneumocystis carinii: analysis of the cellular immune response and characterization of the gene. Mol Microbiol 1993;7:745-53.
37. 37. Chatterton JM, Joss AW, Pennington TH, Ho-Yen DO. Usefulness of rat-derived antigen in the serodiagnosis of Pneumocystis carinii infection. J Med Microbiol 1999;48:681-7.
38. 38. Theus SA, Sawhney N, Smulian G, Walzer P. Proliferative and cytokine responses to human T lymphocytes isolated from human immunodeficiency virus-infected patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 1998;177:238-41.
39. 39. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 1997;65:5052-6.
40. 40. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-53.
41. 41. Korting HC, Schaller M, Eder G, Hamm G, Bohmer U, Hube B. Effects of the immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999;43:2038-41.
42. 42. Lazdins JK, Mestan J, Goutte G, et al. In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus activity of protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997;175:1063-70.